Introduction
One of the most important questions in elective refractive surgery is not “what is the best procedure?” but “what is the best procedure for this specific patient?” EVO ICL delivers excellent outcomes — but only for patients whose anatomy, prescription, and overall ocular health meet defined clinical criteria. When those criteria are met, the procedure is among the most effective and well-tolerated options in modern ophthalmology. When they are not, proceeding would expose the patient to unnecessary risk.
Candidacy for EVO ICL is determined through a structured evaluation process that examines multiple variables simultaneously. No single measurement tells the complete story. A patient with a very high prescription might have a perfect anterior chamber depth; a patient with a moderate prescription might have an endothelial cell count too low to safely proceed. Understanding the full picture is what separates a thorough pre-operative evaluation from a superficial consultation.
This page walks through each major candidacy criterion in detail — what is measured, why it matters, and what the thresholds mean in practical terms. If you are considering EVO ICL, this knowledge will help you interpret your own evaluation results and ask more meaningful questions of your surgeon.
For information on award-winning EVO ICL surgeons who conduct rigorous candidacy assessments, visit the EVO ICL Awards hub.
Section 1: The Core Candidacy Criteria for EVO ICL
Prescription Range
EVO ICL received FDA approval in the United States for the treatment of myopia from -3.00 to -20.00 diopters, with or without astigmatism up to approximately 4.00 diopters (using the toric ICL version). International approvals in some markets extend to hyperopia as well, though hyperopic ICL is less commonly performed.
The lower bound of -3.00 diopters is a regulatory threshold, not a hard clinical limit. Surgeons frequently discuss EVO ICL with patients at lower prescriptions who have other characteristics that make laser correction less ideal — such as thin corneas, large pupils, or chronic dry eye. However, insurance and financing considerations often differ for patients below the labeled range.
At the upper end, EVO ICL’s ability to correct prescriptions up to -20.00 diopters is one of its most clinically significant advantages. LASIK cannot safely address high myopia at this level without removing an unsafe amount of corneal tissue. For patients with severe myopia, EVO ICL is often the only surgical option available. For more on this topic, see EVO ICL for High Prescriptions and Thin Corneas.
Age and Prescription Stability
EVO ICL is FDA-approved for patients between 21 and 45 years of age, though surgeons sometimes implant the lens outside this range when clinical circumstances warrant. The age floor of 21 reflects the typical timeline for prescription stabilization — younger patients frequently experience ongoing myopic progression that would render the ICL’s correction less accurate over time.
Prescription stability is assessed by reviewing the patient’s contact lens or glasses prescription history, typically over one to two years. A prescription that has changed by more than 0.50 diopters in the prior year may indicate ongoing myopic progression. Surgeons may recommend waiting until the prescription has been stable for at least 12 consecutive months before proceeding.
The upper age bound of 45 relates to the onset of presbyopia — the age-related loss of near focusing ability. Patients approaching or experiencing presbyopia may find that EVO ICL alone does not fully address their near vision needs, since the lens corrects distance vision but does not restore accommodative range.
Anterior Chamber Depth
Anterior chamber depth (ACD) is the distance between the front surface of the cornea (the endothelium) and the front surface of the natural crystalline lens. This measurement is critical for EVO ICL because the lens must fit within this space without contacting the iris anteriorly or the natural lens posteriorly.
The minimum ACD for safe EVO ICL implantation is generally considered to be 2.8 millimeters, with many surgeons preferring 3.0 mm or greater. Patients with ACDs below 2.8 mm carry elevated risk of elevated intraocular pressure and inadequate vault, which can cause contact between the ICL and the natural lens — potentially leading to early cataract formation.
ACD is measured using anterior segment OCT, a non-contact imaging technology that provides highly accurate cross-sectional visualization of the anterior eye structures.
Endothelial Cell Density
The corneal endothelium is a single layer of cells lining the back surface of the cornea. These cells are responsible for maintaining corneal clarity by actively pumping fluid out of the corneal stroma. They do not regenerate; their number declines naturally with age and can be reduced by ocular surgery or disease.
Specular microscopy measures endothelial cell density in cells per square millimeter. Healthy young adults typically have densities of 2,500 to 3,000 cells/mm2 or higher. The minimum threshold for safe EVO ICL implantation is generally set at 2,000 cells/mm2, though some surgeons apply more conservative thresholds — particularly for younger patients who have decades ahead during which natural cell loss will continue.
Patients with low endothelial cell counts from previous surgery (including prior corneal transplant, trauma, or other conditions) are poor candidates for EVO ICL or any intraocular procedure.
Section 2: Additional Factors That Influence Candidacy
Pupil Size
While large pupil size is a significant concern in LASIK candidacy — where it contributes to night vision symptoms like haloes and starbursts — it is a less prohibitive factor in EVO ICL candidacy. The ICL corrects vision across the entire optical system of the eye rather than across a specific treatment zone on the corneal surface, so the pupil size threshold that drives LASIK exclusion is not directly applicable.
That said, surgeons still measure pupil size as part of the complete evaluation, as very large pupils can influence the surgeon’s lens sizing calculations and the anticipated optical performance.
Corneal Topography
Unlike LASIK, EVO ICL does not require a specific corneal thickness because no tissue is removed from the cornea. However, corneal topography is still performed as part of the pre-operative work-up to rule out conditions like keratoconus or pellucid marginal degeneration that could affect the eye’s overall optical integrity and post-operative outcomes.
A patient with frank keratoconus may still be evaluated for EVO ICL, but the indication is more complex and requires careful counseling about expectations and potential need for corneal stabilization procedures.
General Ocular and Systemic Health
Conditions that preclude EVO ICL candidacy include:
- Uncontrolled glaucoma: Elevated intraocular pressure is a contraindication because the implant and surgical procedure can temporarily increase pressure.
- Significant cataract: If the natural lens already shows meaningful opacity, implanting an ICL in the same space is not appropriate — cataract surgery addressing both the lens opacity and refractive error simultaneously would be the preferred approach.
- Certain autoimmune conditions: Conditions affecting the immune system or wound healing (lupus, rheumatoid arthritis, and others) may affect surgical candidacy, though each case is evaluated individually.
- Active ocular infection or inflammation: Any acute inflammatory or infectious condition must be fully resolved before surgery.
Systemic medications, including corticosteroids and some psychiatric medications, can affect intraocular pressure and wound healing. A complete medication history is part of every thorough candidacy evaluation.
Section 3: How Outstanding Surgeons Conduct Candidacy Evaluations
Beyond the Checklist
The minimum viable candidacy evaluation covers the metrics described above. Surgeons recognized by the EVO ICL Awards program go further. They take the time to understand each patient’s complete visual lifestyle — their hobbies, occupation, driving habits, near vision demands — and factor these into the procedure recommendation.
A patient who spends eight hours a day reading or working at a computer has different visual priorities than one who primarily drives and plays outdoor sports. The best surgeons calibrate their recommendation accordingly, sometimes recommending monovision strategies or a combination of ICL with other procedures to address a more complete range of visual needs.
Second Opinions and Non-Candidacy
An excellent surgeon will unhesitatingly decline to perform EVO ICL on a patient who does not meet safety criteria — even if that patient is highly motivated. If a surgeon you consult seems to have a “yes” answer for every patient without varying the recommendation based on individual anatomy, this is a warning sign.
Conversely, if a surgeon tells you that you are not a candidate for EVO ICL, ask for specific clinical reasons. A borderline ACD, a prescription slightly outside the labeled range, or low endothelial count are legitimate reasons. “We don’t do that here” or a preference for a different procedure without clinical justification is not.
Section 4: What Patients Should Do Before a Candidacy Evaluation
Preparation Steps
Remove contact lenses before your evaluation. Soft contact lenses should be removed at least one week before your evaluation; rigid gas-permeable lenses should be removed for at least three weeks. Contacts alter corneal curvature, and wearing them to your evaluation can lead to inaccurate topography and refraction measurements.
Bring a complete prescription and vision history. Records from your optometrist documenting prescription changes over the past two to three years give the surgeon a clearer picture of your prescription stability trajectory.
Prepare your questions. Ask specifically about your anterior chamber depth, endothelial cell count, and how the surgeon determines lens sizing. A surgeon who can explain their sizing protocol clearly is demonstrating both technical competence and a patient-centered approach.
Understand that candidacy evaluation is not a commitment. An initial consultation does not obligate you to proceed. Take the information home, review it, and consider a second opinion from a separate qualified practice before scheduling surgery.
For additional guidance on evaluating surgeon qualifications, see EVO ICL Surgeon Credentials: What to Look For and How EVO ICL Surgeons Are Evaluated for Awards.
For information on how EVO ICL compares to LASIK if you are evaluating both options, see EVO ICL vs LASIK: Which Vision Correction Is Right for You?.
Frequently Asked Questions
What is the most common reason patients are not candidates for EVO ICL? Insufficient anterior chamber depth is among the most frequent anatomical disqualifiers. Insufficient endothelial cell density and prescription outside the approved range are also common. See EVO ICL Safety Profile and Clinical Results for context on how surgeons manage these risk factors.
Can I get EVO ICL if I have had LASIK before? In some cases, yes — prior LASIK changes the corneal surface but does not directly affect the anterior chamber. However, detailed evaluation is required, and the surgeon must account for any changes in corneal biomechanics and anterior segment anatomy that resulted from the prior procedure.
Can EVO ICL treat astigmatism? Yes. Toric ICL addresses astigmatism up to approximately 4.00 diopters. Your surgeon will determine whether the standard or toric version of the lens is appropriate based on your refraction. See EVO ICL Surgery: The Complete Procedure Guide for details on lens types.
Is there an upper age limit for EVO ICL? The FDA labeling covers patients up to 45 years of age. Surgeons may proceed in older patients in selected cases, but the increasing presence of natural lens changes and presbyopia makes patient selection more complex for older individuals.
Next Steps
If you believe you may be a candidate for EVO ICL, the next step is a comprehensive pre-operative evaluation with a qualified surgeon. The measurements described in this guide — anterior chamber depth, endothelial cell count, corneal topography, and refraction — are all part of the standard workup and should be performed before any recommendation is made.
Use the EVO ICL Awards directory to identify surgeons with demonstrated expertise in EVO ICL candidacy evaluation and implantation in your region.